Comparative In Vitro Activities of ABT-773 against Aerobic and Anaerobic Pathogens Isolated from Skin and Soft-Tissue Animal and Human Bite Wound Infections
- 1 September 2000
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (9) , 2525-2529
- https://doi.org/10.1128/aac.44.9.2525-2529.2000
Abstract
We studied the comparative in vitro activities of ABT-773, a new ketolide, against 268 aerobic and 148 anaerobic recent isolates from clinical bites using an agar dilution method and inocula of 10 4 CFU/spot for aerobes and 10 5 CFU for anaerobes. The following are the MIC ranges and MICs at which 90% of isolates are inhibited (MIC 90 s) of ABT-773 for various isolates, respectively: Pasteurella multocida and Pasteurella septica , 0.125 to 2 and 1 μg/ml; other Pasteurella species, 0.125 to 1 and 0.5 μg/ml; Corynebacterium spp., 0.015 to 0.06 and 0.015 μg/ml; Staphylococcus aureus , 0.03 to 0.06 and 0.06 μg/ml; coagulase-negative staphylococci, 0.015 to >32 and 32 μg/ml; streptococci, 0.015 to 0.03 and 0.03 μg/ml; Eikenella corrodens , 0.25 to 1 and 1 μg/ml; and Bergeyella zoohelcum , 0.03 to 0.25 and 0.06 μg/ml. For anaerobes the MIC ranges and MIC 90 s of ABT-773 were as follows, respectively: Prevotella heparinolytica , 0.06 to 0.125 and 0.125 μg/ml; Prevotella spp., 0.015 to 0.125 and 0.06 μg/ml; Porphyromonas spp., 0.015 to 0.03 and 0.015 μg/ml; Fusobacterium nucleatum , 0.5 to 8 and 8 μg/ml; other Fusobacterium spp., 0.015 to 8 and 0.5 μg/ml; Bacteroides tectum , 0.015 to 0.5 and 0.06 μg/ml; and Peptostreptococcus spp., 0.015 to 0.25 and 0.03 μg/ml. ABT-773 was more active than all macrolides tested against S. aureus , E. corrodens , and anaerobes, but all compounds were poorly active against F. nucleatum . The activity of ABT-773 was within 1 dilution of that of azithromycin against Pasteurella spp., and ABT-773 was four- to eightfold more active than clarithromycin against Pasteurella spp. ABT-773 may offer a therapeutic alternative for bite wound infections.Keywords
This publication has 9 references indexed in Scilit:
- Manual of Clinical Microbiology, 8th Edition:Manual of Clinical Microbiology, 8th EditionClinical Infectious Diseases, 2004
- In vitro activity of HMR 3004 (RU 64004) against 502 strains of anaerobic bacteriaAnaerobe, 1999
- Bacteriologic Analysis of Infected Dog and Cat BitesNew England Journal of Medicine, 1999
- Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) Compared to Those of Erythromycin, Azithromycin, Clarithromycin, Roxithromycin, and Eight Other Antimicrobial Agents against Unusual Aerobic and Anaerobic Human and Animal Bite Pathogens Isolated from Skin and Soft Tissue Infections in HumansAntimicrobial Agents and Chemotherapy, 1998
- Erythromycin failure with subsequent Pasteurella Multocida meningitis and septic arthritis in a cat-bite victimAnnals of Emergency Medicine, 1990
- Pasteurella multocida Meningitis in an Adult: Case Report and ReviewClinical Infectious Diseases, 1990
- Reclassification of the Genus Pasteurella Trevisan 1887 on the Basis of Deoxyribonucleic Acid Homology, with Proposals for the New Species Pasteurella dagmatis, Pasteurella canis, Pasteurella stomatis, Pasteurella anatis, and Pasteurella langaaInternational Journal of Systematic and Evolutionary Microbiology, 1985
- Effect of Carbon Dioxide on ErythromycinAntimicrobial Agents and Chemotherapy, 1983
- Effect of carbon dioxide on in vitro susceptibility of anaerobic bacteria to erythromycinAntimicrobial Agents and Chemotherapy, 1981